[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exercise-performance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exercise-performance":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,54,94,120,171,196,226,256,293,327,357,378,394,408,455,478],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100637581","effect-of-hot-spring-therapy-on-cognitive-function-recovery-during-altitude-training-100637581",false,"NCT07608913","Effect of Hot Spring Therapy on Cognitive Function Recovery During Altitude Training","A Randomized Controlled Trial Investigating the Effects of Balneotherapy on Cognitive Performance, Cerebral Hemodynamics, and Exercise Capacity in Healthy Adults Undergoing Simulated Altitude Training","Inclusion Criteria:\n\n* Male or female aged 11-17 years- Regular endurance training (≥3 sessions\u002Fweek) for ≥2 years\n* No history of altitude exposure \\>2000m in the past 3 months\n* No contraindications to hot water immersion (e.g., uncontrolled hypertension, severe cardiovascular disease, open wounds, pregnancy)\n* Ability to provide written informed consent\n* Willingness to abstain from other recovery modalities (e.g., massage, cryotherapy, compression garments) during the study period\n* No color blindness or uncorrected visual impairment that would affect Stroop test performance\n\nExclusion Criteria:\n\n* History of cardiovascular, respiratory, renal, or endocrine disorders\n* Current use of medications affecting autonomic function or cognition (e.g., beta-blockers, anticholinergics, stimulants, sedatives)\n* History of syncope, heat intolerance, or neurological disorders\n* Acute musculoskeletal injury within the past 6 months- Regular use of sauna, hot tub, or spa within the past month- Pregnancy or breastfeeding (for female participants)\n* Shift work or trans-meridian travel within 2 weeks prior to baseline assessment- Alcohol consumption \\>14 units\u002Fweek or smoking\n* History of traumatic brain injury, stroke, or psychiatric disorders",true,"ALL","11 Years","17 Years",{"count":21,"type":22},27,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized controlled trial aims to investigate the effects of hot spring bath therapy on cognitive function recovery, cerebral hemodynamics, and athletic performance in athletes undergoing altitude training. Participants will be randomly assigned to either a hot spring intervention group, a hot water control group, or a blank control group. The hot spring intervention group receives hot spring baths (38°C, 20 minutes) combined with altitude training; the hot water control group receives hot water baths (38°C, 20 minutes) combined with altitude training; and the blank control group receives standard recovery procedures combined with altitude training. Primary outcome measures include cognitive performance assessments (Stroop test, psychomotor vigilance test) and cerebral hemodynamic indicators (functional near-infrared spectroscopy, transcranial Doppler ultrasound). Secondary outcomes included exercise capacity (maximal oxygen uptake, triathlon performance, 500-meter test), blood lactate, and hematological parameters (white blood cells, neutrophils, platelets). These findings may provide evidence for non-pharmacological interventions to enhance cognitive recovery and brain adaptation during altitude training.",[28,29,30,31,32,33,34],"Altitude Training Adaptation","Cognitive Function","Cerebral Hemodynamics","Exercise Performance","Hydrotherapy","Balneotherapy","Hypoxia",[36,37,38,39,32,40],"Altitude Sickness","Cognition","Cerebrovascular Circulation","Physical Performance","Hot Springs","RECRUITING","2026-05-19",{"date":44,"type":45},"2026-05-27","ACTUAL",{"date":47,"type":22},"2026-05-25",{"date":49,"type":22},"2026-06-25",{"name":51,"class":52},"Macao Polytechnic University","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":16,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":67,"conditions":68,"keywords":75,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100637590","effects-of-creatine-and-heat-exposure-on-exercise-performance-and-body-water-distribution-100637590","NCT07593014","Effects of Creatine and Heat Exposure on Exercise Performance and Body Water Distribution","Creatine Monohydrate Supplementation During Repeated Heat Exposure: Effects on Fluid Balance and Exercise Performance in a Randomized Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Healthy biological males between 18 and 27 years of age\n* Recreationally active males and varsity athletes\n* Able to safely participate in moderate-intensity exercise and heat exposure\n* Willing to maintain habitual diet and physical activity throughout the study\n* Willing to refrain from additional dietary supplementation during study participation\n* Able to attend all required laboratory visits and heat exposure sessions\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* History of cardiovascular, metabolic, respiratory, renal, neurological, or heat-related illness\n* Contraindications to exercise testing or heat exposure identified during health screening\n* Current musculoskeletal injury limiting exercise participation\n* Current use of creatine supplementation or inability to complete the required washout period\n* Current use of medications or supplements known to affect hydration, thermoregulation, cardiovascular function, or exercise performance\n* Known allergy or intolerance to creatine monohydrate, maltodextrin, or orange juice\n* Inability to comply with study procedures or supplementation protocol\n* Resting tympanic temperature ≥38.0°C prior to a heat exposure session\n* Participation in another research study that may interfere with this protocol","MALE","18 Years","27 Years",{"count":65,"type":22},25,[25],"The goal of this clinical trial is to learn whether creatine supplementation changes how the body adapts to repeated exercise in the heat in healthy recreationally active adults and varsity athletes. The study will also examine whether creatine affects fluid balance, blood volume changes and exercise performance.\n\nThe main questions it aims to answer are:\n\nDoes creatine supplementation increase plasma volume and total body water during repeated heat exposure more than placebo? Does creatine supplementation improve exercise performance after heat acclimation more than placebo? Does creatine supplementation influence cardiovascular responses to heat stress?\n\nResearchers will compare a creatine supplementation group to a placebo group to determine whether creatine changes the magnitude of heat acclimation adaptations.\n\nParticipants will:\n\nComplete baseline measurements of body composition, hydration, blood markers, and exercise performance.\n\nConsume either creatine monohydrate or a placebo supplement daily Complete repeated supervised exercise sessions in a controlled heated environment Undergo repeated assessments of body water, temperature, heart rate, and exercise performance throughout the study",[69,31,70,71,72,73,74],"Heat Exposure","Hydration","Body Fluid Compartments","Creatine Supplementation","Placebo - Control","Plasma Volume",[76,69,77,78,74,79,71,80,81,82,83],"Creatine Monohydrate","Heat Acclimation","Short Term Heat Acclimation","Fluid Balance","Wingate Test","VO2 Max","Cardiorespiratory Performance","Musculoskeletal Performance","NOT_YET_RECRUITING","2026-05-11",{"date":87,"type":45},"2026-05-18",{"date":89,"type":22},"2026-07-30",{"date":91,"type":22},"2027-08-30",{"name":93,"class":52},"University of Windsor",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":16,"sex":17,"minAge":62,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100635744","effect-of-high-level-headphone-sound-exposure-on-exercise-responses-in-young-healthy-individuals-100635744","NCT07556666","Effect of High-Level Headphone Sound Exposure on Exercise Responses in Young Healthy Individuals","The Effect of High-Level Headphone Sound Exposure on Cardiorespiratory Responses and Perceived Exertion","Inclusion Criteria:\n\n* Healthy adults aged 18 to 30 years\n* Male or female participants\n* No regular exercise habit\n* Voluntary participation with written informed consent\n\nExclusion Criteria:\n\n* Any cardiopulmonary, neurological, or musculoskeletal disease\n* Any acute cardiovascular, respiratory, or musculoskeletal complaint\n* Infection, fever, dizziness, fatigue, or similar temporary health problem on the test day\n* Alcohol consumption within 12 hours before testing\n* Caffeine consumption within 3 hours before testing\n* Vigorous physical activity within 24 hours before testing\n* Inability to complete the exercise protocol or withdrawal from the study","30 Years",{"count":103,"type":22},38,"OBSERVATIONAL","This study will investigate the effect of high-level headphone sound exposure on cardiorespiratory responses and perceived exertion during a submaximal treadmill exercise test in young healthy individuals. Healthy volunteers aged 18 to 30 years will complete two exercise sessions under two different conditions: zero-sound and high-level sound exposure. Heart rate, oxygen saturation, blood pressure, and perceived exertion will be evaluated before, during, and after exercise.",[107,31],"Sound Exposure",[109,110],"Noise","Exercise","2026-04-24",{"date":113,"type":45},"2026-04-29",{"date":115,"type":22},"2026-05-01",{"date":117,"type":22},"2027-05-01",{"name":119,"class":52},"Saglik Bilimleri Universitesi",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":16,"sex":61,"minAge":62,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":147,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":53},"100629969","impact-of-training-load-on-the-gut-microbiome-and-its-relation-to-exercise-performance-muscle-phenotype-and-markers-of-overreaching-in-healthy-men-100629969","NCT07481578","Impact of Training Load on the Gut miCrobiome And Its Relation to exeRcise Performance, mUscle Phenotype, and markerS of Overreaching in Healthy Men","ICARUS: Impact of Training Load on the Gut Microbiome and Its Relation to Exercise Performance, Muscle Phenotype, and Markers of Overreaching in Healthy Men: Phase A - Human Trial","ICARUS","Inclusion criteria:\n\n* Males between 18 and 45 years old.\n* Recreationally active individuals, with a weekly exercise training volume between one and six hours per week.\n* Good health status confirmed by a sport medical screening, which includes a sport medical questionnaire and resting electrocardiogram.\n* Body Mass Index (BMI) between 18.5 and 27.5 kg\u002Fm².\n* Masters the Dutch language.\n\nExclusion criteria:\n\n* Engagement in strenuous competitive sports one month prior to or during the study intervention.\n* Medication and vaccination: Pro- or antibiotic treatment during the past three months, non-steroidal anti-inflammatory drugs (NSAIDs) or cholestyramine during the past month, drugs interfering with intestinal permeability (e.g., prokinetics, laxatives, lubiprostone, loperamide, anti-spasmodics, linaclotide, proton pump inhibitors) during the past month. Vaccinations within one month prior to or during the study intervention.\n* Blood donations within three months or plasma donation within one month prior to or during the study intervention.\n* Inflammatory bowel disease (Crohn or colitis ulcerosa) or celiac disease.\n* Diagnosed irritable bowel syndrome.\n* Intake of any performance-enhancing medication or nutritional supplements known to modulate the gut microbiome in the two months prior to or during the study.\n* Substance abuse, including alcohol consumption of more than three units\u002Fday (weekly average).\n* Any injury or pathology considered a contraindication for performing physical exercise, as determined by the medical doctor overseeing the preparticipation medical screening.\n* No access to smartphone and\u002For computer with internet access.\n* No willingness to use the Polar Flow app and MijnEetmeter to collect physical activity, heart rate, sleep, and food intake data.\n* Concomitant participation in another interventional trial, without approval from the research team.\n* Any other reasons considered by the research team that the participant will not complete the study.","45 Years",{"count":130,"type":22},45,[25],"The goal of this study is to learn how different amounts of supervised indoor cycling training change gut health (gut bacteria, the substances gut bacteria make, and the gut barrier integrity), and how these changes relate to changes in fitness, muscle health, and signs of doing too much training (a state called 'overreaching'). The study includes healthy, recreationally active men aged 18 to 45 years.\n\nThe primary questions, for which the study is powered (sufficient participants included), are:\n\n1. Does moderate load training change blood and faecal levels of butyrate (a short-chain fatty acid made by gut bacteria) after eight weeks compared with a control group?\n2. Compared to moderate load training, do higher training loads lead to different responses in blood and faecal levels of butyrate?\n\nResearchers will compare:\n\n* A control group that does not complete structured training;\n* A moderate-load training group that completes eight weeks of supervised cycling (4x\u002Fweek);\n* A high-load training group that completes four weeks of moderate-load training followed by four weeks of higher training load (twice the number of training sessions).\n\nParticipants will:\n\n* Be randomly assigned to one of the three groups;\n* Complete 8 weeks of supervised indoor cycling sessions if assigned to a training group;\n* Complete four study assessment periods (baseline, after week four, after week eight, and after a short taper (rest period);\n* Provide blood, stool, skeletal muscle, urine, saliva, and breath samples during the assessment periods;\n* Complete fitness and performance tests and questionnaires during the assessment periods.",[110,134,135,136,31,137,138,139,140,141,142,143,144,145,146],"Overreaching","Butyrate","Gut Microbiome","Skeletal Muscle","Glucose Tolerance","Hormones","Vascular Health","Muscle Adaptation","Physical Fitness","Heart Rate Variability (HRV)","Anthropometric Measurements","Metabolic Health","Food Intake",[148,149,150,151,152,153,154,155,134,156,157,158,143,159,160,161],"Exercise training","Training load","Overload training","Fecal butyrate","Gut health","Exercise performance","Muscle phenotype","Physical fitness","Glucometabolic health","Vascular health","Muscle adaptation","Anthropometrics","Metabolic health","Food intake","2026-03-16",{"date":164,"type":45},"2026-03-19",{"date":166,"type":45},"2024-10-07",{"date":168,"type":22},"2027-05-31",{"name":170,"class":52},"Stefan De Smet",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":16,"sex":61,"minAge":62,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":4},"100629324","beetroot-beverage-and-repeated-sprint-power-output-during-rast-100629324","NCT07473193","Beetroot Beverage and Repeated Sprint Power Output During RAST","\"Effects of a Beetroot-Based Functional Beverage on Repeated Sprint Performance: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial\"","Inclusion Criteria:\n\n* Healthy trained athletes\n\nAge between 18-35 years\n\nRegular training ≥3 times\u002Fweek\n\nNo cardiovascular or metabolic disease\n\nExclusion Criteria:Healthy trained athletes\n\nAge between 18-35 years\n\nRegular training ≥3 times\u002Fweek\n\nNo cardiovascular or metabolic disease\n\n\\-","35 Years",{"count":180,"type":22},10,[25],"This randomized, double-blind, placebo-controlled crossover trial aims to evaluate the acute effects of a nitrate-rich beetroot-based beverage on repeated sprint performance in trained athletes.\n\nTen athletes will complete two experimental conditions in randomized order: beetroot beverage (BET) and placebo (PLA), separated by a 7-day washout period. The beetroot beverage consists of 200 mL of a mixture containing beetroot, cocoa, and green tea, providing approximately 6.4 mmol of nitrate.\n\nIn each condition, participants will perform a Running Anaerobic Sprint Test (RAST), consisting of six maximal 35-meter sprints with 10 seconds of passive recovery between sprints. The primary outcome is mean power output across the six sprints.\n\nSecondary outcomes include fatigue index, sprint-by-sprint power output, heart rate, rating of perceived exertion (Borg 6-20 scale), maximal oxygen uptake (VO₂max), and sleep quality assessed using the Insomnia Severity Index (ISI).",[184,31,185],"Repeated Sprint Performance in Trained Athletes","Nitrate Supplementation",[187],"Beetroot juice","2026-03-10",{"date":162,"type":45},{"date":191,"type":22},"2026-03-12",{"date":193,"type":22},"2026-04-30",{"name":195,"class":52},"Universidad Autonoma de Chihuahua",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":16,"sex":61,"minAge":62,"maxAge":101,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":211,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":53},"100624481","resistance-training-adaptations-and-caffeine-intake-100624481","NCT07410195","Resistance Training Adaptations and Caffeine Intake","Study of Different Caffeine Supplementation Strategies on Resistance Training-Induced Adaptations","Inclusion Criteria:\n\n* Male sex and age between 18-30 years\n* No history of caffeine use or very low habitual intake (\\\u003C50 mg\u002Fday)\n* No participation in a regular resistance training program in the past 6 months\n* Body mass index (BMI) between 18.5-30 kg\u002Fm2\n* Willingness to attend all training and testing sessions regularly\n* Provision of written informed consent after being fully informed about the study\n\nExclusion Criteria:\n\n* Presence of cardiovascular, metabolic, renal, hepatic, or other serious chronic diseases\n* Diagnosed psychiatric disorders or severe caffeine intolerance\u002Fallergy\n* Use of medications affecting caffeine metabolism or muscle anabolism (e.g., beta-blockers, antidepressants, anabolic steroids)\n* Musculoskeletal injuries that prevent safe resistance training\n* Smoking or alcohol consumption at levels that could affect study outcomes\n* Concurrent participation in another exercise intervention study\n* Inability to tolerate DXA scanning, blood sampling, or D2O ingestion procedures",{"count":204,"type":22},180,[25],"This randomized, double-blind, placebo-controlled crossover trial investigates the effects of three different caffeine supplementation strategies on resistance training-induced adaptations in 180 caffeine-naive, inactive young adult males. Participants will undergo two 4-week supervised resistance training programs separated by a 2-week washout\u002Fcrossover period. The three caffeine strategies are: (1) constant daily low-moderate dosing (3 mg\u002Fkg\u002Fday), (2) gradually escalating dose (3 to 6 mg\u002Fkg across weeks), and (3) training-day-only caffeine (3 mg\u002Fkg\u002Fday). Primary outcomes include non-invasive measures of integrated anabolism and hypertrophy (D2O-derived plasma proteomic fractional synthesis rate, DXA muscle volume) and strength metrics. Secondary outcomes include hormonal responses (insulin, cortisol, testosterone, IGF-1), sleep\u002Frecovery parameters, and adverse effects.",[208,31,209,210],"Muscle Hypotrophy","Muscle Strength","Adaptation",[212,213,141,214,215,216],"Caffeine","Resistance Training","Supplementation","Strength Training","Hypertrophy","2026-02-07",{"date":219,"type":45},"2026-02-13",{"date":221,"type":22},"2026-02-20",{"date":223,"type":22},"2026-04-20",{"name":225,"class":52},"Istanbul University - Cerrahpasa",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":16,"sex":17,"minAge":62,"maxAge":128,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":235,"briefSummary":236,"conditions":237,"keywords":242,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":53},"100584862","effects-of-lentil-protein-hydrolysate-on-blood-pressure-control-vascular-function-and-exercise-performance-100584862","NCT06894875","Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance","Examining the Safety and Tolerability of Lentil Protein Hydrolysate in Healthy Males and Females Whilst Exploring the Effects of a Dose Range on Blood Pressure Control and Vascular Function and Exercise Performance","Inclusion Criteria:\n\n* Willing to provide written and dated informed consent to participate in the study.\n* Willing and able to comply with the protocol.\n* Are not on any medication, or supplements which would impact the trial in the opinions of the investigator or Sponsor.\n* Male or female between 18 and 45 years of age (18.5 kg\u002Fm2 ≥ BMI \\\u003C 30 kg\u002Fm2).\n* Comply with ACSM guidelines for physical activity.\n* Have not participated in a clinical trial within the past month and agree to not participate in another clinical trial during the study period.\n* Agree to not significantly alter diet or exercise routine during the trial period.\n* Willing to wear a wearable device continuously for the duration of the study\n\nExclusion Criteria:\n\n* Subjects having a known allergy or hypersensitivity to any of the ingredients in the investigational products.\n* Subjects with a history of alcohol and\u002For other drug abuse in the past year.\n* Has performed strenuous exercise (rating of perceived exertion ≥ 13) ≤ 48 hours before laboratory visit (Borg, 1982).\n* Consuming \\>14 alcoholic drinks per week or \\> 2 drinks\u002Fday in the 48 hours preceding a clinic visit.\n* Active smokers, nicotine use or vaping\n* Subjects suffering from a sleep disorder and\u002For who have a known history of (or was being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s) that might put the subject at risk and\u002For confounded the results of the study.\n* Subjects with a history of being diagnosed with phenylketonuria or another disease affecting amino acid metabolism (i.e., maple syrup urine disease, etc.).\n* Subjects with an elevated resting heart rate (\\>100 bpm) or blood pressure (systolic BP \\>140 mmHg or diastolic BP \\>90 mmHg).\n* Pregnant or lactating women\n* Presentation of orthostatic hypotension during the screening and familiarisation study visit\n* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.",{"count":234,"type":22},48,[25],"Examining the safety and tolerability of Lentil Protein Hydrolysate in healthy males and females whilst exploring the effects of a dose range on blood pressure control and vascular function and exercise performance",[110,238,239,240,31,241],"Blood Pressure","Vasodilation","Vascular Function in Healthy Volunteers","Safety and Tolerability in Healthy Volunteers",[153,243,244,245],"Vascular function","blood pressure control","Lentil protein hydrolysate","2025-12-15",{"date":248,"type":45},"2025-12-16",{"date":250,"type":45},"2025-06-24",{"date":252,"type":22},"2026-03-30",{"name":254,"class":255},"Nuritas Ltd","INDUSTRY",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":16,"sex":17,"minAge":62,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":273,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":53},"100567804","dose-response-impact-of-glucosyl-hesperidin-citrapeak-on-exercise-performance-blood-flow-stress-cognition-and-other-perceptual-indicators-100567804","NCT06672952","Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators","HES","Inclusion Criteria:\n\n1. Participants who are between 18 - 50 years of age\n2. Body mass index values will range from \\>25.0 \\\u003C 30.0 kg\u002Fm2\n3. The average body mass index for entire study cohort will be less than 27.0 kg\u002Fm2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 27.0 kg\u002Fm2\n4. Free-living and independent\n5. In good health absent of being overweight or mildly obese with no other signs or symptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal disease or disorders\n6. Willingness to maintain consistent sleep duration the evening before study visits\n7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures\n8. Regular completion of at least 180 minutes of moderate to vigorous exercise per week for the past 6 months\n\nExclusion Criteria:\n\n1. Not currently completing at least 180 minutes of moderate to vigorous exercise per week for the past 6 months\n2. Positive medical history and\u002For is currently being treated for some form of heart disease, cardiovascular disease\n3. Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals\n4. Has liver disease or some form of clinically diagnosed hepatic impairment\n5. Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL)\n6. Diagnosed with or is being treated for some form of thyroid disease\n7. Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year\n8. Diagnosed with some form of immune disorder (i.e., HIV\u002FAIDS)\n9. History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n10. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)\n11. Positive medical history for any neurological condition or neurological disease\n12. Currently prescribed a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.)\n13. Current smoker (average of \\> 1 pack per day within the past 3 months) has quit within the past six months. This includes all forms of nicotine\n14. Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to weight loss such as thermogenics, hydroxycitric acid, ephedra, capsaicin, etc.\n15. Participants who are lactating, pregnant or planning to become pregnant\n16. Have a known sensitivity or allergy to any of the study products\n17. History of alcohol or substance abuse in the 12 months prior to screening\n18. Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol\n19. Any orthopedic limitation that would prevent participation in a general fitness program\n20. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data","50 Years",{"count":265,"type":22},60,[25],"The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.",[31,269,29,270,271,272],"Exercise Recovery","Nitric Oxide","Blood Flow","Endurance Exercise",[274,275,276,277,278,279,280,281,282,283],"exercise performance","aerobic capacity","anaerobic power","mood","nitric oxide","cognitive function","glucosyl-hesperidin","training readiness","fuel utilization","endothelial function","2025-12-05",{"date":286,"type":45},"2025-12-12",{"date":288,"type":45},"2025-04-15",{"date":290,"type":22},"2026-01-01",{"name":292,"class":52},"Lindenwood University",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":16,"sex":300,"minAge":301,"maxAge":263,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":307,"conditions":308,"keywords":312,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":53},"100612376","phase-2-effect-of-a-short-term-multi-strain-probiotic-supplementation-in-endurance-athletes-100612376","NCT07252778","Effect of a Short-term Multi-strain Probiotic Supplementation in Endurance Athletes","Effect of a Short-term Multi-strain Probiotic Supplementation on the Exercise- Associated Gastrointestinal Disturbances in Trained Female Athletes Under Controlled Conditions During Professional Training Cycle","Inclusion Criteria:\n\n* belonging to the national rowing team;\n* training experience ≥5 years;\n* a currently issued medical certificate confirming\n* good health and capacity to practice sports;\n* good health without chronic health disorders;\n* written informed consent to participate.\n\nExclusion Criteria:\n\n* injury, any health contraindication or failure to perform exercise procedures;\n* gastrointestinal infections, diseases, disorders;\n* past history of gastrointestinal surgery, and\n* other self-reported gastrointestinal issues;\n* reporting symptoms of infection or taking any medication (e.g. antibiotics) for 4 weeks before the study protocol;\n* current supplementation of prebiotics,\n* probiotics, synbiotics (last 4 weeks);\n* current intake of pharmaceutical agents (e.g., nonsteroidal anti-inflammatory drugs, laxatives, antidiarrhea agents, antacids, and\u002For antiemetics) (last 4 weeks);\n* failure to follow the study protocol;\n* declared general feeling of being unwell;\n* pregnancy or current pregnancy planning.","FEMALE","16 Years",{"count":303,"type":22},30,[305,306],"PHASE2","PHASE3","The aim of this project is to evaluate and identify the effect of a short-term 2-week multi-strain probiotic (MPRO) supplementation on the exercise-associated gastrointestinal (GI) symptoms and perturbations in high level female athletes of the Polish national team during strictly controlled conditions of a training camp, based on recommendations for best practices for probiotic (PRO) research in athletes and assessment of EX-associated GI perturbations.",[309,310,31,311,214],"Sports Nutrition","Biochemical Markers","Aerobic Capacity",[313,314,315,316,317],"Probiotics","Gastro-intestinal markers","Microbiota","Rowing","Females","2025-11-18",{"date":320,"type":45},"2025-11-28",{"date":322,"type":22},"2025-11-20",{"date":324,"type":22},"2027-06-30",{"name":326,"class":52},"Krzysztof Durkalec-Michalski",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":16,"sex":17,"minAge":62,"maxAge":178,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":341,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":53},"100594860","short-term-effects-of-caffeine-and-a-multi-ingredient-pre-workout-on-exercise-performance-100594860","NCT07024940","Short-term Effects of Caffeine and a Multi-ingredient Pre-workout on Exercise Performance","Acute Effects of Coffee, Anthocyanin-Caffeine Supplement and Placebo on Exercise Performance Markers","Inclusion Criteria:\n\n* Are a healthy male or female adult aged 18-35 years old\n* Regularly engaged in resistance training or aerobic exercise at least 3 times per week, at least 30 minutes a week for the past 6 months\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Have a history of or currently have a cardiovascular or metabolic disease (e.g., diabetes, prediabetes, hypertension, arrhythmia, heart attack, stroke, non-alcoholic fatty liver disease, chronic kidney disease)\n* History of seizure disorder\n* Currently taking prescription medications (e.g., beta-blockers, antidepressants, anti-anxiety, pain killers)\n* Currently pregnant, breastfeeding, pregnant within the past year, or a chance of being pregnant\n* Recent participation in another clinical trial\n* Any sensitivities to caffeine, coffee, berries, maltodextrin, monk fruit extract, or any known food allergies\n* Currently undertaking serious exercise training (6 or more days of the week)\n* Recently started taking creatine or beta-alanine daily within the past 3 months. (If greater than 3 months taken consistently is okay)",{"count":335,"type":22},12,[25],"The investigators are conducting a study to see how a commercial pre-workout supplement, coffee, and water affect how well people perform. The study is conducted across four visits. The first visit is to assess the participants, and the next three visits are for testing. Each participant will drink a randomly assigned beverage 45 minutes before testing. Throughout the study, the participants will complete three testing days-each at least three days apart-so they can try all three drinks. The first test is the Wingate test, where the participants pedal as fast as they can for 30 seconds against a set resistance. The second test is a 1-mile treadmill run\u002Fwalk on an incline, where the participant tries to complete the distance as fast as possible. The third test measures reaction time using light-up buttons to see how quickly a participant responds by touching them. These tests will help determine if any of the drinks improve performance. The results can help people choose the best drink for their workouts or races.",[339,340,31],"Coffee","Anthocyanins",[339,212,342,343,344,345,346,347],"Wingate","Anthocyanin-Caffeine","1-mile","VO2 max","pre-workout","supplement","2025-08-15",{"date":350,"type":45},"2025-08-19",{"date":352,"type":45},"2025-04-25",{"date":354,"type":22},"2026-09-01",{"name":356,"class":52},"St. Louis University",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":16,"sex":17,"minAge":62,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":53},"100521246","u-labaics-effects-on-exercise-performance-indacaterol-100521246","NCT06067100","U-LABA\u002FICS Effects on Exercise Performance, Indacaterol","Physiological Response to U-LABA\u002FICS With Emphasis on Exercise Performance, Indacaterol","Inclusion Criteria:\n\n* Age 18-39\n* Physically active \\> 5 h weekly\n* Maximal oxygen consumption classified as high or very high\n\nExclusion Criteria:\n\n* Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist\u002Fcorticosteroid\n* ECG abnormality\n* ACQ score \\> 1.5\n* Severe bronchial hyperreactivity as determined by mannitol test\n* FEV1\u002FFVC ratio \\\u003C 0.7 determined with spirometry\n* Chronic illness determined to be a potential risk for participant during study\n* In chronic treatment with medication that may interfere with study results\n* Pregnancy\n* Smoker\n* Blood donation during the past 3 months","39 Years",{"count":303,"type":22},[25],"The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate",[31],"2025-04-07",{"date":371,"type":45},"2025-04-09",{"date":373,"type":45},"2024-01-15",{"date":375,"type":22},"2026-12-01",{"name":377,"class":52},"Morten Hostrup, PhD",{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":16,"sex":17,"minAge":62,"maxAge":364,"enrollmentInfo":384,"targetDuration":4,"studyType":23,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":393,"locationsCount":53},"100521208","u-labaics-effects-on-exercise-performance-vilanterol-100521208","NCT06066606","U-LABA\u002FICS Effects on Exercise Performance, Vilanterol","Physiological Response to U-LABA\u002FICS With Emphasis on Exercise Performance, Vilanterol",{"count":303,"type":22},[25],"The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate",[31],{"date":389,"type":45},"2025-04-10",{"date":391,"type":45},"2023-10-03",{"date":375,"type":22},{"name":377,"class":52},{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":16,"sex":17,"minAge":62,"maxAge":364,"enrollmentInfo":400,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":406,"leadSponsor":407,"locationsCount":53},"100522009","role-of-lung-function-for-exercise-capacity-in-well-trained-individuals-100522009","NCT06077019","Role of Lung Function for Exercise Capacity in Well-trained Individuals","Role of Lung Function, Airway Inflammation and Bronchial Hyper Reactivity for Exercise Capacity in Well-trained Individuals",{"count":265,"type":22},[25],"The purpose of the project is to investigate exercise performance in humans following prolonged inhalation of beta2-agonists vilanterol + fluticasone furoate or indacaterol + mometasone furoate",[31],{"date":371,"type":45},{"date":391,"type":45},{"date":375,"type":22},{"name":377,"class":52},{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":16,"sex":17,"minAge":62,"maxAge":128,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":418,"briefSummary":419,"conditions":420,"keywords":429,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":454,"locationsCount":53},"100577217","a-randomized-double-blind-study-to-assess-the-effect-of-a-postbiotic-on-oxidative-stress-and-exercise-performance-100577217","NCT06795425","A Randomized, Double-Blind Study to Assess the Effect of a Postbiotic on Oxidative Stress and Exercise Performance","A Randomized, Double-Blinded, Placebo-Controlled, Parallel Study, to Assess the Effect of a Novel Postbiotic Blend on Exercise Induced Oxidative Stress Markers and Exercise Performance","PBE","INCLUSION CRITERIA\n\nTo be eligible for inclusion, the participant must fulfill all of the following criteria:\n\n1. Male or female participants between 18 - 45 years of age\n2. Signed informed consent.\n3. Health, which is defined as currently not being treated for an active cardiac, pulmonary, metabolic, immunological, neurological, respiratory, orthopedic, musculoskeletal, psychiatric, or reproductive disease or disorder. With research team and principal investigator discretion, some ongoing treatments will be permitted if a determination is made that the treatment will not increase risk of study participation and the treatment or illness itself will not confound with desired study outcomes.\n4. Physically active, which is defined as performing aerobic or resistance-based physical exercise between 2 and 5 times per week at a rating of perceived intensity (RPE) of 4 or greater (out of 10)\n5. Body mass index values will range from \\>18.5 to \\\u003C 29.9 kg\u002Fm2 (Inclusive)41 (Weir and Jan 2024).\n6. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures.\n\nEXCLUSION CRITERIA\n\nParticipants will be excluded from the study if they meet any of the following criteria:\n\n1. Body mass index \\\u003C18.5 to \\\u003C29.9 kg\u002Fm2 (Inclusive)\n2. Use of antibiotics or probiotics in the previous 3 months\n3. Positive medical history and\u002For is currently being treated for some form of heart or cardiovascular, neurological impairment, disease or condition, immune disorder or disease, thyroid disease, kidney disease, renal failure, regular dialysis, liver disease or other diagnosed hepatic impairment.\n4. Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL)\n5. Diagnosed with major affective disorder or other significant psychiatric disorder or disturbance that required hospitalization or home intervention in the prior year.\n6. History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n7. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, bile acid malabsorption, H.pylori infection, small intestine bacterial overgrowth (SIBO), celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)\n8. Recently prescribed or change in dosage (within the past 6 months) of statin drug (i.e., Lipitor, Livalo, Crestor, Zocor, etc.), hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.), or psychiatric medications.\n9. Consumption (any dose or amount) of any nicotine-containing product (cigarette, cigar, vaping, etc.)\n10. Participants who are lactating, pregnant or planning to become pregnant.\n11. History of alcohol or substance abuse in the 12 months prior to screening\n12. Receipt or use of an investigational product in another research study within 60 days of beginning the study protocol.\n13. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data.\n14. Extensive travel (\\>1 month) that will disrupt original outline of the study protocol.\n15. Participant is consuming a biotic product (pre-, pro-, syn-, or post-) or alters their diet resulting in a change in the amount of prebiotic, probiotic, or fermented foods that are consumed while in the study protocol.",{"count":417,"type":22},80,[25],"This is a prospective, randomized, placebo controlled, double-blind study to assess the effects of a postbiotic blend on exercise induced oxidative stress markers and exercise performance in healthy adult.",[421,422,423,424,425,426,427,31,428],"Oxidative Stress","Healthy","Exercise-induced Muscle Damage","Exercise-induced Muscle Soreness","Immune Function","Gut Health","Microbiome Analysis","Exercise Metabolism",[430,431,432,433,274,434,435,436,437,438,439,440,441,442,443,444,445,446,447],"oxidative stress","antioxidants","postbiotics","ergogenic aid","muscle damage","recovery","gut microbiome","immune function","sleep quality","anxiety","recreationally active","inflammation","endurance training","fecal microbiota","nutritional supplement","aerobic exercise","biomarkers","clinical trial","2025-01-21",{"date":450,"type":45},"2025-01-28",{"date":452,"type":22},"2025-02-01",{"date":290,"type":22},{"name":292,"class":52},{"id":456,"slug":457,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":16,"sex":17,"minAge":62,"maxAge":178,"enrollmentInfo":462,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":53},"100472157","clinical-study-to-evaluate-the-effects-of-two-novel-hydration-beverage-formulas-on-rehydration-in-healthy-adults-100472157","NCT05428228","Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults","A Randomized, Placebo Controlled, Semi-Blind, Crossover Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults","Inclusion Criteria:\n\n* Healthy adult male and female participants who are between 18 and 49 years of age (inclusive). Are in good general health (no active or uncontrolled diseases or conditions) and can ingest the assigned amount of fluid at each visit. Have a body mass index (BMI) between 17.0 and 29.9 kg\u002Fm2 (inclusive). Exercise regularly as per physical activity guidelines for Americans \\[structured exercise for a minimum of 150 cumulative minutes per week (low end) to 500 cumulative minutes of exercise per week (high-end)\\] and willing to maintain the same level of physical activity throughout the study period. Can maintain their exercise status at the beginning of the study throughout the study period. Can achieve a peak VO2 at screening that is at least 60% of their age and gender matched normative value per American College of Sports Medicine recommendations. Have normal or acceptable to the investigator vital signs (BP and HR) at screening. Individuals with childbearing potential: Agree to have urine pregnancy test performed on each trial day. Able to agree to the requirements and restrictions of this study, willing to give voluntary consent, able to understand and read the questionnaires, and carry out all study-related procedures.\n\nExclusion Criteria:\n\n* Female participants who are lactating, pregnant or planning to become pregnant during the study. Carry a diagnosis of diabetes. Weigh less than or equal to 80 pounds at any visits. Answer \"yes\" to any of the questions asked on the screening questionnaire (Appendix 10.2.1). Have a history of a diagnosis of celiac disease, chronic pancreatitis, steatorrhea, unstable thyroid disease, major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorder (i.e., HIV\u002FAIDS), cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit). Use any dietary supplements that may impact hydration status within the 30 days prior to the baseline visit (Familiarization Trial\u002FVisit 2). Participants must observe a 30-day washout period of no supplementation to be eligible. Consume more than two standard alcoholic drinks per day. Use of inhalables, smokables, or the like (e.g., cigarettes, vaporizers, water pipes, or cannabis) within 30 days prior to the first dose of the study product or for the duration of the study. Have a medical condition that may impact ability to exercise or ability to ingest prescribed fluid volume. Smoking tobacco products.",{"count":5,"type":22},[25],"The aim of the clinical trial is to evaluate the efficacy of two novel hydration products on rehydration following exercise.",[466,467,31,269,468],"Dehydration","Rehydration","Cognitive Performance","2024-07-26",{"date":471,"type":45},"2024-07-29",{"date":473,"type":45},"2022-10-01",{"date":475,"type":22},"2024-09-01",{"name":477,"class":52},"Liquid I.V.",{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":16,"sex":17,"minAge":62,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":53},"100553707","creatine-supplementation-at-simulated-altitude-100553707","NCT06489587","Creatine Supplementation At Simulated Altitude","Inclusion Criteria:\n\n* 18-40 years old\n* BMI 18.5 to 40 kg\u002Fm2\n* Habitually active (\\>150 minutes per week of moderate-vigorous physical activity)\n\nExclusion Criteria:\n\n* Pregnant or trying to become pregnant\n* Recent use of creatine supplementation\n* Supplemental allergies","40 Years",{"count":265,"type":22},[25],"Creatine supplementation has been shown to increase exercise performance at sea level. The goal of this study is to determine the effects of creatine supplementation on exercise performance at simulated altitude.",[31],"2024-07-03",{"date":491,"type":45},"2024-07-08",{"date":493,"type":45},"2024-06-25",{"date":495,"type":22},"2026-06",{"name":497,"class":52},"California Polytechnic State University-San Luis Obispo"]